drug_type
RELEVANT_DRUG
intervention_type
Vaccine (DNA plasmid)
drug_description
Plasmid DNA vaccine encoding HPV16/18 E6/E7 tumor antigens designed to prime HPV-specific cellular and humoral immune responses.
nci_thesaurus_concept_id
C198007
nci_thesaurus_preferred_term
HPV 16/18 E6/E7 DNA Vaccine pBI-11
nci_thesaurus_definition
A therapeutic codon-optimized DNA vaccine encoding for the E6 and E7 proteins of human papillomavirus (HPV) subtypes 16 and 18, with potential immunostimulating and antineoplastic activities. Upon administration, the HPV 16/18 E6/E7 DNA vaccine pBI-11 expresses the HPV 16/18 E6/E7 fusion protein which may elicit a specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HPV 16/18 E6 and E7 oncoproteins, resulting in tumor cell lysis. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis. Codon optimization of the HPV16/18 E6/E7 genes in pBI-11 improves fusion protein expression.
drug_mesh_term
Vaccines, DNA
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Plasmid DNA vaccine encoding codon‑optimized HPV16/18 E6/E7 antigens. Following uptake by host cells, the plasmid drives expression of the E6/E7 fusion protein, which is processed and presented on MHC class I and II to elicit HPV‑specific cytotoxic T‑cell, helper T‑cell, and humoral responses. This immune activation targets and lyses tumor cells expressing HPV16/18 E6/E7 oncoproteins.
drug_name
pBI-11
nct_id_drug_ref
NCT05799144